Clin Mol Hepatol.  2021 Apr;27(2):273-277. 10.3350/cmh.2021.0019.

Negligible risk of hepatocellular carcinoma in chronic hepatitis B patients in immune-tolerant phase: Myth or fact

Affiliations
  • 1Medical Data Analytics Centre, The Chinese University of Hong Kong, Hong Kong SAR, China
  • 2Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong SAR, China
  • 3Institute of Digestive Disease, The Chinese University of Hong Kong, Hong Kong SAR, China

Keyword

Hepatitis B; Immune tolerance; Fibrosis-4 index; Liver fibrosis
Full Text Links
  • CMH
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr